Related Experiment Video
Updated: Feb 26, 2026

Cell Population Analyses During Skin Carcinogenesis
Published on: August 21, 2013
[Basal cell carcinoma and the modalities of its therapy]
Abstract:
Basal cell carcinoma (BCC) also known as basalioma or basal cell cancer, is the most common skin cancer. BCC has a very low metastatic risk. This tumor can cause significant disfigurement by invading surrounding tissues. It occurs mainly in fair-skinned patients with a family history of this cancer. Sunlight is a factor in about two-thirds of these cancers. Standard surgical excision is the treatment of choice. Mohs micrographic surgery is an outpatient or inpatient procedure in which the tumor is surgically excised and then immediately examined under a microscope. Cryosurgery is an old modality for the treatment of many skin cancers. Other treatment options incl. photodynamic therapy, topical immunotherapy, radiation or targeted therapy will be discussed.
More Related Videos
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

